Novel superactive leptin antagonists and their potential therapeutic applications

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 659-665

  Gertler, Arieh ^a   Elinav, Eran ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Antagonist; Anti autoimmune diseases; Cancer; Inflammatory disease; Leptin; T2DM model; Uremic cachexia

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BILIRUBIN; CALCIUM; CHOLESTEROL; CISPLATIN; CREATININE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INSULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN ANTAGONIST; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PEPTIDE HORMONE ANTAGONIST; PHOSPHORUS; POTASSIUM; PROTEIN BCL 2; PROTEIN BCL XL; RESISTIN; STAT3 PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; APPETITE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; BLOOD BRAIN BARRIER; BODY WEIGHT; BONE MARROW CELL; BREAST CANCER; CACHEXIA; CALORIC INTAKE; CANCER INHIBITION; CANCER MORTALITY; CANCER REGRESSION; CANCER STEM CELL; CARCINOGENESIS; CELL ACTIVATION; CELL DENSITY; CELL MATURATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; CONCANAVALIN A-INDUCED HEPATITIS; CYTOKINE RELEASE; DENDRITIC CELL; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL ENRICHMENT; ESOPHAGUS CANCER; EXPERIMENTAL ARTHRITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL COLITIS; FAT CONTENT; FATTY LIVER; FIBROSIS; FOOD INTAKE; GALLBLADDER CANCER; GLIOBLASTOMA; GLUCONEOGENESIS; GLUCOSE TOLERANCE; HEART DISEASE; HEART VENTRICLE HYPERTROPHY; HEMATOPOIETIC SYSTEM; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY CANCER; LAMINA PROPRIA; LEPTIN DEFICIENCY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FIBROSIS; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METABOLIC SYNDROME X; MICROFLORA; MONOCYTE; MULTIPLE SCLEROSIS; MUSCLE FUNCTION; MUTAGENESIS; MUTATION; NATURAL KILLER CELL; NEPHRITIS; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OVARY CANCER; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; RECTUM CANCER; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; STEATOSIS; STELLATE CELL; STEM CELL; STOMACH CANCER; SUSCEPTIBLE POPULATION; SYMPATHETIC NERVE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; THYMUS ATROPHY; TRIPLE NEGATIVE BREAST CANCER; TUMOR PROMOTION; UREMIA; UREMIC CACHEXIA; UTERUS CANCER; WEIGHT CHANGE; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; LEPTIN; LIGANDS; MUTANT PROTEINS; RECEPTORS, LEPTIN; RECOMBINANT PROTEINS;

EID: 84894105717     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990014     Document Type: Review

References (97)

1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
2. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-71.
3. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206-9.
4. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J. The ins and outs of leptin receptor activation. FEBS Lett 2003; 546: 45-50.
5. Fong TM, Huang RR, Tota MR, et al. Localization of leptin binding domain in the leptin receptor. Mol Pharmacol 1998; 53: 234-40.
6. Sandowski Y, Raver N, Gussakovsky EE, et al. Subcloning, expression, purification, and characterization of recombinant human leptin-binding domain. J Biol Chem 2002; 277: 46304-9.
7. Niv-Spector L, Raver N, Friedman-Einat M, et al. Mapping leptininteracting sites in recombinant leptin-binding domain (LBD) subcloned from chicken leptin receptor. Biochem J 2005; 390: 475-84.
8. Zabeau L, Defeau D, Van der Heyden J, Iserentant H, Vandekerckhove J, Tavernier J. Functional analysis of leptin receptor activation using a Janus kinase/signal transducer and activator of transcription complementation assay. Mol Endocrinol 2004; 18: 150-61.
9. Chow D, He X, Snow AL, Rose-John S, Garcia KC. Structure of an extracellular gp130 cytokine receptor signaling complex. Science 2001; 291: 2150-5.
10. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alphareceptor/ gp130 complex. Science 2003; 300: 2101-4.
11. Muller-Newen G. The cytokine receptor gp130: faithfully promiscuous. Sci STKE 2003; 2003: PE40.
12. Peelman F, Van Beneden K, Zabeau L, et al. Mapping of the leptin binding sites and design of a leptin antagonist. J Biol Chem 2004; 279: 41038-46.
13. Callebaut I, Labesse G, Durand P, et al. Deciphering protein sequence information through hydrophobic cluster analysis (HCA): current status and perspectives. Cell Mol Life Sci 1997; 53: 621-45.
14. Niv-Spector L, Gonen-Berger D, Gourdou I, et al. Identification of the hydrophobic strand in the A-B loop of leptin as major binding site III: implications for large-scale preparation of potent recombinant human and ovine leptin antagonists. Biochem J 2005; 391: 221-30.
15. Salomon G, Niv-Spector L, Gussakovsky EE, Gertler A. Largescale preparation of biologically active mouse and rat leptins and their L39A/D40A/F41A muteins which act as potent antagonists. Protein Expr Purif 2006; 47: 128-36.
16. Elinav E, Niv-Spector L, Katz M, et al. Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology 2009; 150: 3083-91.
17. Shpilman M, Niv-Spector L, Katz M, et al. Development and characterization of high affinity leptins and leptin antagonists. J Biol Chem 2011; 286: 4429-42.
18. Niv-Spector L, Shpilman M, Boisclair Y, Gertler A. Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist. Protein Expr Purif 2012; 81: 186-92.
19. Cipolletta D, Kolodin D, Benoist C, Mathis D. Tissular T(regs): a unique population of adipose-tissue-resident Foxp3+CD4+ T cells that impacts organismal metabolism. Semin Immunol 2011; 23: 431-7.
20. Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol 2010; 31: 228-35.
21. Sarraf P, Frederich RC, Turner EM, et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997; 185: 171-5.
22. Gimble JM, Robinson CE, Wu X, Kelly KA. The function of adipocytes in the bone marrow stroma: an update. Bone 1996; 19: 421-8.
23. Sanchez-Margalet V, Martin-Romero C, Gonzalez-Yanes C, Goberna R, Rodriguez-Bano J, Muniain MA. Leptin receptor (Ob-R) expression is induced in peripheral blood mononuclear cells by in vitro activation and in vivo in HIV-infected patients. Clin Exp Immunol 2002; 129: 119-24.
24. Motivala SJ, Dang J, Obradovic T, Meadows GG, Butch AW, Irwin MR. Leptin and cellular and innate immunity in abstinent alcoholics and controls. Alcohol Clin Exp Res 2003; 27: 1819-24.
25. Lam QL, Liu S, Cao X, Lu L. Involvement of leptin signaling in the survival and maturation of bone marrow-derived dendritic cells. Eur J Immunol 2006; 36: 3118-30.
26. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-71.
27. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 2003; 133: 11-9.
28. Tian Z, Sun R, Wei H, Gao B. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun 2002; 298: 297-302.
29. Montecucco F, Bianchi G, Gnerre P, Bertolotto M, Dallegri F, Ottonello L. Induction of neutrophil chemotaxis by leptin: crucial role for p38 and Src kinases. Ann N Y Acad Sci 2006; 1069: 463-71.
30. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897-901.
31. De Rosa V, Procaccini C, Cali G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007; 26: 241-55.
32. Matarese G, Di Giacomo A, Sanna V, et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 2001; 166: 5909-16.
33. Elinav E, Pappo O, Sklair-Levy M, et al. Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping. J Pathol 2006; 209: 121-8.
34. Elinav E, Pappo O, Sklair-Levy M, et al. Amelioration of nonalcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. J Pathol 2006; 208: 74-81.
35. Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004; 81: 223-41.
36. Palmer G, Gabay C. A role for leptin in rheumatic diseases? Ann Rheum Dis 2003; 62: 913-5.
37. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313-25.
38. Sanna V, Di Giacomo A, La Cava A, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003; 111: 241-50.
39. Matarese G, Carrieri PB, La Cava A, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2005; 102: 5150-5.
40. Batocchi AP, Rotondi M, Caggiula M, et al. Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol 2003; 139: 150-4.
41. Bokarewa M, Tarkowski A. Local infusion of infliximab for the treatment of acute joint inflammation. Ann Rheum Dis 2003; 62: 783-4.
42. Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M. Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 1999; 48: 745-8.
43. Vadacca M, Margiotta D, Rigon A, et al. Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 2009; 36: 295-7.
44. Chung CP, Long AG, Solus JF, et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009; 18: 799-806.
45. De Sanctis JB, Zabaleta M, Bianco NE, Garmendia JV, Rivas L. Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 2009; 42: 272-4.
46. Rho YH, Solus J, Sokka T, et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009; 60: 1906-14.
47. Fraser DA, Thoen J, Reseland JE, Forre O, Kjeldsen-Kragh J. Decreased CD4+ lymphocyte activation and increased interleukin-4 production in peripheral blood of rheumatoid arthritis patients after acute starvation. Clin Rheumatol 1999; 18: 394-401.
48. Matarese G, Sanna V, Lechler RI, et al. Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes 2002; 51: 1356-61.
49. Lee CH, Chen YG, Chen J, et al. Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis. Diabetes 2006; 55: 171-8.
50. Elinav E, Ali M, Bruck R, et al. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology 2009; 49: 278-86.
51. Siegmund B, Lehr HA, Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology 2002; 122: 2011-25.
52. Siegmund B, Sennello JA, Jones-Carson J, et al. Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut 2004; 53: 965-72.
53. Sitaraman S, Liu X, Charrier L, et al. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. Faseb J 2004; 18: 696-8.
54. Fantuzzi G, Sennello JA, Batra A, et al. Defining the role of T cellderived leptin in the modulation of hepatic or intestinal inflammation in mice. Clin Exp Immunol 2005; 142: 31-8.
55. Mattioli B, Straface E, Quaranta MG, Giordani L, Viora M. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol 2005; 174: 6820-8.
56. Karmiris K, Koutroubakis IE, Kouroumalis EA. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 847-55.
57. Ballinger A, Kelly P, Hallyburton E, Besser R, Farthing M. Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the pathogenesis of anorexia and weight loss. Clin Sci (Lond) 1998; 94: 479-83.
58. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Kouroumalis EA. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2007; 19: 789-94.
59. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 2011; 13: 71-6.
60. Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci 2011; 16: 1634-50.
61. Teucher B, Rohrmann S, Kaaks R. Obesity: focus on all-cause mortality and cancer. Maturitas 2010; 65: 112-6.
62. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 15: 556-65.
63. Food Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. World Cancer Research Fund/American Institute for Cancer Research: Washington, DC 2007.
64. Systematic Literature Review Continuous Update Project Report. The Associations between Food, Nutrition and Physical Activity and the Risk of Colorectal Cancer. World Cancer Research Fund/American Institute for Cancer Research 2010.
65. Lawrence JE, Cook NJ, Rovin RA, Winn RJ. Leptin promotes glioblastoma. Neurol Res Int 2012; 2012: 870807.
66. Ellerhorst JA, Diwan AH, Dang SM, et al. Promotion of melanoma growth by the metabolic hormone leptin. Oncol Rep 2010; 23: 901-7.
67. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004; 10: 4325-31.
68. Uddin S, Bu R, Ahmed M, et al. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 2009; 8: 74.
69. Hoon Kim J, Lee SY, Myung SC, Kim YS, Kim TH, Kim MK. Clinical significance of the leptin and leptin receptor expressions in prostate tissues. Asian J Androl 2008; 10: 923-8.
70. Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 2012.
71. Feldman DE, Chen C, Punj V, Tsukamoto H, Machida K. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A 2011; 109: 829-34.
72. McGlothen T, Gillespie C, Colbert L, Guo S, Gonzalez-Perez R. Leptin signaling impacts on notch and Wnt crosstalk in breast cancer. CTRC-AACR San Antonio Breast Cancer Symposium: San Antonio 2011.
73. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001; 121: 79-90.
74. Aparicio T, Kotelevets L, Tsocas A, et al. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. Gut 2005; 54: 1136-45.
75. Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D, Barrett KE. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007; 94: 346-54.
76. Luongo C, Moser AR, Gledhill S, Dove WF. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res 1994; 54: 5947-52.
77. Endo H, Hosono K, Uchiyama T, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011; 60: 1363-71.
78. Padidar S, Farquharson AJ, Williams LM, et al. Leptin upregulates pro-inflammatory cytokines in discrete cells within mouse colon. J Cell Physiol 2011; 226: 2123-30.
79. Drew JE. Molecular mechanisms linking adipokines to obesityrelated colon cancer: focus on leptin. Proc Nutr Soc 2012; 71: 175-80.
80. Manolakopoulos S, Bethanis S, Liapi C, et al. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol 2007; 7: 17.
81. Stefanou N, Satra M, Papanikolaou V, et al. Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. Exp Biol Med (Maywood) 2006; 231: 1653-63.
82. Wang SN, Lee KT, Ker CG. Leptin in hepatocellular carcinoma. World J Gastroenterol 2010; 16: 5801-9.
83. Kitade M, Yoshiji H, Kojima H, et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 983-91.
84. Elinav E, Abd-Elnabi A, Pappo O, et al. Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation. J Hepatol 2006; 44: 529-36.
85. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-9.
86. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-9.
87. Wang SN, Chuang SC, Yeh YT, et al. Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol 2006; 59: 1267-71.
88. Morash B, Li A, Murphy PR, Wilkinson M, Ur E. Leptin gene expression in the brain and pituitary gland. Endocrinology 1999; 140: 5995-8.
89. Riolfi M, Ferla R, Del Valle L, et al. Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol 2010; 20: 481-9.
90. Yeh WL, Lu DY, Lee MJ, Fu WM. Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia 2009; 57: 454-64.
91. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 2004; 188: 560-5.
92. Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer 2011; 104: 128-37.
93. Liu H, Wan D, Pan Z, et al. Expression and biological significance of leptin, leptin receptor, VEGF, and CD34 in colorectal carcinoma. Cell Biochem Biophys 2011; 60: 241-4.
94. Knight BB, Oprea-Ilies GM, Nagalingam A, et al. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer 2011; 18: 413-28.
95. Cao L, Liu X, Lin EJ, et al. Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell 2010; 142: 52-64.
96. Teta D. Adipokines as uremic toxins. J Ren Nutr 2012; 22: 81-5.
97. Odamaki M, Furuya R, Yoneyama T, et al. Association of the serum leptin concentration with weight loss in chronic hemodialysis patients. Am J Kidney Dis 1999; 33: 361-8.